Contact us

877-469-1TRM
424-208-8866

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Pancreatic Cancer GS-6624 II Closed to Accrual